ReviewCurrent drug delivery2025
Advancing Small Nucleic Acid Drug Delivery: From Stability Challenges to Novel Therapeutic Applications.
Review in Current drug delivery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Recent Advances in Non-Viral Vectors for Gene Therapy and Gene Delivery: From Lipid Nanoparticles to Engineered Extracellular Vesicles.Pharmaceutics · 2026Review
- RNA Regulatory Networks: Key Hubs in the Panorama of Cancer and Emerging Therapeutic Targets.MedComm · 2026Review
- Stem Cell Nanotechnology Applications as Drug Delivery Systems for Cancer Therapy: A New Era in Targeted Treatment.Current pharmaceutical design · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small nucleic acids (sNA) are revolutionizing several therapeutic environments in areas such as oncology as well as rare disease states. However, despite the progress in RNA modification, lipid nanoparticles (LNPs), and GalNAc conjugation methods, issues like toxicity, immunogenicity, and stability limitations affect the application. Compared with viral and non-viral systems, LNPs have become more credible carriers to solve the problems of RNA degradation and realize more innovation, such as the first RNA interference drug, Patisiran. Likewise, methods for GalNAc conjugation have enabled liver-targeting therapies with better pharmacokinetic profiles. Relative to this subject, novel strategies such as exosome-mediated delivery and multifaceted systems involving LNP-GalNAc and exosome all hold more specificity and biostability. Some of the recent advancements in RNA chemical modifications involve the application of 1-methylpseudouridine which enhances the stability of the RNA and also reduces its immunogenic outcomes. Also, the application of AI in therapeutic areas includes establishing the delivery vectors, estimating severe side effects, and designing new nucleic acid therapies. In addition to hepatic targeting, tissue targetability is now being investigated for other purposes. A solution to the existing stability and targeting limitations is critical for the further development and enhanced use of sNA therapies in broad diseases, including chronic and complex diseases. The major focus of this review is on the recent development and potential future trends of sNA as a drug delivery system for precision medicine.
Indexed as
Identifiers
39817375What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.